IFNG and cirrhosis of liver: Ruether et al. compared the levels of SARS-CoV-2-specific IFN-γ 29 days after the second dose of the mRNA vaccine (Pfizer-BioNTech or Moderna) or vector-based vaccine (AstraZeneca) in 3 groups: 19 healthy controls (mean around 1000 mIU/mL), 26 patients with liver cirrhosis (mean between 100 and 200 mIU/mL or borderline), and 82 liver transplant patients (mean below 100 mIU/mL or negative response) [30].